Guideline Recommendations for Evaluation, Prevention, and Management of Renal Stones

Initial Evaluation and Diagnostic Workup

• Obtain a detailed medical and dietary history that emphasizes fluid intake, protein, calcium, sodium, and medications known to promote stone formation. 1
• Perform serum chemistries—including electrolytes, calcium, creatinine, and uric acid—to uncover underlying metabolic abnormalities. 1
• Conduct a urinalysis with dipstick and microscopic evaluation to determine urine pH and detect characteristic crystals. 1
• Analyze stone composition at least once when material is available; the identified type (e.g., uric acid, cystine, struvite, calcium oxalate, calcium phosphate) directly guides therapeutic strategy. 2, 1
• Review imaging to quantify stone burden; the presence of multiple or bilateral stones signals a higher risk of recurrence. 2, 1
• Measure serum intact parathyroid hormone when primary hyperparathyroidism is suspected (elevated or high‑normal serum calcium). 2, 1

Metabolic Testing

• Perform a 24‑hour urine collection in all patients with recurrent stones and in first‑time stone formers who are high‑risk (multiple stones, bilateral disease, nephrocalcinosis, or strong family history). 2, 1
• Analyze the urine for total volume, pH, calcium, oxalate, uric acid, citrate, sodium, potassium, and creatinine. 2, 1
• Collect two separate 24‑hour specimens when feasible to account for day‑to‑day variability. 2
• Add urinary cystine measurement if cystine stones are known or suspected, or if there is a family history of cystinuria. 2
• Suspect primary hyperoxaluria when urinary oxalate exceeds 75 mg/day in adults without bowel dysfunction. 2

Dietary Recommendations (Universal and Stone‑Specific)

• Encourage a target urine output of ≥ 2.5 L per day through increased fluid consumption; this is the single most critical intervention for all stone types. Grade B evidence. 2
• Observational data suggest that coffee, tea, wine, and orange juice may lower stone risk, whereas sugar‑sweetened beverages increase risk. 2
• For calcium stones with hypercalciuria:
  
  • Limit dietary sodium to ≤ 2,300 mg/day to reduce urinary calcium excretion. 2
  • Maintain normal dietary calcium intake of 1,000–1,200 mg/day; low‑calcium diets paradoxically raise stone risk by increasing oxalate absorption. Grade B evidence. 2
• For cystine stones: restrict sodium and animal protein intake in addition to fluid augmentation. 3

Pharmacological Therapy by Stone Type

• Calcium stones with hypercalciuria – prescribe thiazide diuretics as first‑line therapy, continuing dietary sodium restriction; monitor for hypokalemia and glucose intolerance. 3
• Calcium stones with hypocitraturia – use potassium citrate to raise urinary citrate to ≥ 400 mg/day and increase urine pH; dosing ranges from 30 mEq/day (mild) to 60 mEq/day (severe), with a maximum studied dose of 100 mEq/day. 3
• Uric acid stones – initiate urinary alkalinization with potassium citrate to achieve a urine pH of ≈ 6.0, enhancing uric acid solubility. 3
• Allopurinol is not recommended as first‑line therapy for uric acid stones because low urine pH, not hyperuricosuria, is the predominant defect. 3
• Cystine stones – first‑line management includes high fluid intake (≥ 4 L/day), sodium/protein restriction, and urinary alkalinization with potassium citrate to reach a urine pH of ≈ 7.0. 3
• If the above measures are insufficient or stone burden remains high, prescribe tiopronin (alpha‑mercaptopropionylglycine); it is more effective and has fewer adverse events than d‑penicillamine. 3
• Struvite stones – monitor for recurrent infection and consider urease inhibition with acetohydroxamic acid when appropriate, recognizing its significant side‑effect profile. 3

Surgical Pre‑Operative Requirements

• Obtain a non‑contrast computed tomography (CT) scan before percutaneous nephrolithotomy (PCNL); this is a strong recommendation. 4, 5
• Perform a urinalysis prior to any stone‑related intervention. 4, 5
• If infection is suspected based on urinalysis or clinical signs, acquire a urine culture and treat with appropriate antibiotics before proceeding. 4, 5
• Select the definitive treatment modality based on stone size, anatomical location, composition, and overall burden. 4, 5

Follow‑Up Monitoring

• Within six months of initiating therapy, obtain a single 24‑hour urine specimen to evaluate the metabolic response (e.g., urinary citrate, pH). 3
• Conduct annual 24‑hour urine collections thereafter, or more frequently if stone activity persists, to assess adherence and ongoing metabolic risk. 3
• Perform periodic blood tests to detect adverse effects of medications (e.g., hypokalemia with thiazides, hyperkalemia with potassium citrate, hepatic enzyme elevation with allopurinol or tiopronin, anemia with acetohydroxamic acid or tiopronin). 3
• Repeat stone analysis when new material becomes available, especially in patients who are not responding to current management, as stone composition may evolve. 3

Common Pitfalls to Avoid

• Do not restrict dietary calcium in patients with calcium stones; doing so increases oxalate absorption and stone risk. 2
• Do not use allopurinol as first‑line therapy for uric acid stones; urinary alkalinization addresses the primary pathophysiology. 3
• Do not discontinue metabolic monitoring after stones have cleared; ongoing surveillance identifies patients who become refractory to therapy. 3
• Do not overlook medication side effects; regular laboratory monitoring is essential to prevent serious complications. 3

Management of Kidney Stones

Initial Evaluation and Risk Stratification

• The American Urological Association recommends obtaining stone analysis at least once to guide specific preventive measures, as stone composition directly determines treatment strategy 6
• Metabolic testing with 24-hour urine collections should be performed in all recurrent stone formers and high-risk first-time formers, analyzing for total volume, pH, and other factors 6
• Review of imaging studies is necessary to quantify stone burden and identify patients at higher risk of recurrence 6
• Serum intact parathyroid hormone level should be obtained if primary hyperparathyroidism is suspected 6
• Urinalysis, including dipstick and microscopic evaluation, should be performed to assess urine pH and identify crystals pathognomonic of stone type 7

Dietary Management

• Increased fluid intake to achieve urine volume of at least 2.5 liters daily is the single most important intervention across all stone types 6, 8
• For calcium stones, normal dietary calcium intake of 1,000-1,200 mg per day should be maintained, and sodium intake should be limited to 2,300 mg daily 6
• For cystine stones, target higher fluid intake of at least 4 liters per day to decrease urinary cystine concentration below 250 mg/L 8
• Restricting sodium and protein intake is recommended for cystine stones 9

Pharmacological Management

• Thiazide diuretics are first-line therapy for calcium stones with hypercalciuria, combined with continued dietary sodium restriction 6, 8
• Potassium citrate therapy is indicated for calcium stones with hypocitraturia to increase urinary citrate and inhibit stone formation 6, 8
• Potassium citrate is first-line therapy for uric acid stones to increase urinary pH to approximately 6.0, enhancing uric acid solubility 6, 8
• For cystine stones, first-line therapy includes increased fluid intake, sodium and protein restriction, and urinary alkalinization with potassium citrate to raise urinary pH to approximately 7.0 9, 8
• Tiopronin should be offered as next-line therapy for cystine stones if initial modifications are insufficient 9, 8

Follow-Up Monitoring

• A 24-hour urine specimen should be obtained within six months of initiating treatment to assess response to dietary and/or medical therapy 9, 6, 8
• Annual 24-hour urine specimens should be obtained after initial follow-up, or more frequently depending on stone activity, to assess patient adherence and metabolic response 9, 8
• Periodic blood testing should be performed to assess for adverse effects in patients on pharmacological therapy, such as hypokalemia and glucose intolerance with thiazides 9, 6, 8